Hypertension is an extremely common noncom-municable condition affecting an estimated
1.3 billion adults (aged 30–79 years) worldwide and with a prevalence that has doubled …

Small interfering RNAs (siRNAs) targeting hepatic angiotensinogen (Agt) may provide long-
lasting antihypertensive effects, but the optimal approach remains unclear. Here, we …

Dose-Related Reductions in Blood Pressure with a RNA Interference (RNAi) Therapeutic
Targeting Angiotensinogen in Hypertensive P Page 1 Dose-Related Reductions in Blood …

Background A single dose of small interfering RNA (siRNA) targeting liver angiotensinogen
eliminates hepatic angiotensinogen and lowers blood pressure. Angiotensinogen …

Blood pressure management involves antihypertensive therapies blocking the renin-
angiotensin system (RAS). Yet, it might be inadequate due to poor patient adherence or the …

Targeting angiotensinogen with RNA-based therapeutics is a promising new tool to treat
hypertension and diseases beyond. Their long-lasting effects are particularly exciting, and if …

Background and Purpose Small interfering RNA (siRNA) targeting liver angiotensinogen
lowers blood pressure, but its effects in hypertensive diabetes are unknown. Experimental …

Hypertension remains the leading cause of cardiovascular disease and premature death
globally, affecting half of US adults. A high proportion of hypertensive patients exhibit …

Small interfering RNA (siRNA) targeting liver angiotensinogen (AGT) lowers blood pressure,
but its effectiveness in hypertensive chronic kidney disease is unknown. Considering that …

Small interfering RNA (siRNA) represents a novel, fascinating therapeutic strategy that
allows for selective reduction in the production of a specific protein through RNA …